PD-RX Pharmaceuticals Inc (PDRX) Stock Analysis
Verdict: WATCH (do not buy)
Cash-rich balance sheet trading below net liquid assets is offset by continuous multi-year revenue contraction and severe OTC illiquidity.
Investment score: 47/100
Analysis as of
Is PD-RX Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
The model views PDRX as a classic microcap asset-play holding $3.99/share in cash against a $3.10 share price, but weighed down by shrinking revenues and severe OTC trading illiquidity.
7-factor investment score
- Valuation: 65/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
PD-RX Pharmaceuticals Inc opportunities and risks
What speaks for PDRX
- Balance sheet trading at a 22% discount to cash holdings alone ($3.99 cash/share vs $3.10 stock price).
What speaks against PDRX
- Revenue has shrunk 36% from $28.71M in FY22 to $18.35M in FY25.
Frequently asked questions about PD-RX Pharmaceuticals Inc (PDRX)
Is PDRX stock a good investment?
The TradeMates model rates PD-RX Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 47/100. The model views PDRX as a classic microcap asset-play holding $3.99/share in cash against a $3.10 share price, but weighed down by shrinking revenues and severe OTC trading illiquidity. This is algorithmic model output, not personal investment advice.
Is PDRX stock a buy?
The TradeMates model verdict for PDRX is WATCH (do not buy) with an investment score of 47/100. Treat this as a model signal to review, not a personal buy recommendation.